Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel

Population prevalence of diagnosed primary immunodeficiency diseases in the United States

Publication ,  Journal Article
Boyle, JM; Buckley, RH
Published in: Pharmaceuticals Policy and Law
January 1, 2008

Rationale: Although health surveys are routinely used to estimate the population incidence and prevalence of many chronic and acute conditions in the US population, they have infrequently been used for "rare" conditions such as primary immunodeficiency diseases (PID). Accurate prevalence measures are needed to separate the truly rare condition from those that primary care doctors are likely to see in their practices today, if early diagnosis and treatment are to be achieved. Methods: A national probability sample of 10,000 households was sampled by random digit dialing and screened by telephone to identify how many of the nearly 27,000 household members had been diagnosed with a PID. Results: A total of 23 household members in 18 households were reported with a specific diagnosis for PID (CVID, IgA, IgG, XLA, SCID, CGD), whereas additional cases were reported as a PID without a confirmatory diagnosis. These findings suggest a population prevalence of diagnosed PID in the United States at approximately 1 in 1,200 persons. Conclusions: Diagnoses of PID in the United States are far more common than suggested in the literature. © 2008 Network of Centres for Study of Pharmaceutical Law.

Duke Scholars

Published In

Pharmaceuticals Policy and Law

EISSN

2210-495X

ISSN

1389-2827

Publication Date

January 1, 2008

Volume

10

Start / End Page

99 / 108
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Boyle, J. M., & Buckley, R. H. (2008). Population prevalence of diagnosed primary immunodeficiency diseases in the United States. Pharmaceuticals Policy and Law, 10, 99–108.
Boyle, J. M., and R. H. Buckley. “Population prevalence of diagnosed primary immunodeficiency diseases in the United States.” Pharmaceuticals Policy and Law 10 (January 1, 2008): 99–108.
Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. Pharmaceuticals Policy and Law. 2008 Jan 1;10:99–108.
Boyle, J. M., and R. H. Buckley. “Population prevalence of diagnosed primary immunodeficiency diseases in the United States.” Pharmaceuticals Policy and Law, vol. 10, Jan. 2008, pp. 99–108.
Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. Pharmaceuticals Policy and Law. 2008 Jan 1;10:99–108.

Published In

Pharmaceuticals Policy and Law

EISSN

2210-495X

ISSN

1389-2827

Publication Date

January 1, 2008

Volume

10

Start / End Page

99 / 108